Alexion Pharmaceuticals (ALXN)

Add to Watchlists
Create an Alert
149.80 +0.75  +0.50% NASDAQ Apr 17, 8:00PM BATS Real time Currency in USD
View Full Chart
ALXN Price Chart
View All Events

ALXN Events

Date Type Description
Apr 24 Misc Alexion Pharmaceuticals, Inc. Q1 2014 Earnings Conference Call
Apr 24 Earnings Alexion Pharmaceuticals, Inc. Q1 2014 Earnings Results. Estimate: 1.04.
Jan 30 Misc Alexion Pharmaceuticals Q4 2013 Earnings Conference Call
Jan 30 Earnings Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Results on Thursday, January 30, 2014. Estimate: 0.73.
Oct 24 Misc Q3 2013 Alexion Pharmaceuticals Earnings Conference Call
Oct 24 Earnings Alexion Pharmaceuticals to Report Third Quarter 2013 Results on Thursday, October 24, 2013. Estimate: 0.71.
Jul 25 Misc Q2 2013 Alexion Pharmaceuticals Earnings Conference Call
Jul 11 Earnings Alexion Pharmaceuticals to Report Second Quarter 2013 Results on Thursday, July 25, 2013. Estimate: 0.60.
May 06 Misc AGM Event for Alexion Pharmaceuticals Inc.
Apr 25 Misc Alexion Pharmaceuticals to Report First Quarter 2013 Conference Call
View All Performance Charts

ALXN Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Alexion Pharmaceuticals is up 58.10% over the last year vs S&P 500 Total Return up 22.72%, Amgen up 7.42%, and Regeneron Pharmaceuticals up 39.26%.

Get Quote for

PDF Report for ALXN

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download ALXN Pro Report PDF

Portfolio Strategies Featuring ALXN

Did Alexion Pharmaceuticals make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

ALXN Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: Connecticut
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Research and Development in Biotechnology
  • NAICS Code: 541711
  • NAICS Industry: Scientific Research and Development Services
  • NAICS Industry Code: 5417
  • NAICS Sector: Professional, Scientific, and Technical Services
  • NAICS Sector Code: 54

Alexion Pharmaceuticals, Inc. (Alexion), incorporated in 1992, is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeutic areas of hematology, nephrology (including transplant rejection), neurology, ophthalmology and cancer. Alexion’s marketed product, Soliris (eculizumab), is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). On January 28, 2011, Alexion acquired Taligen Therapeutics, Inc. (Taligen). On February 10, 2011, Alexion acquired patents and assets from Germany-based Orphatec Pharmaceuticals GmbH (Orphatec) related to an investigational therapy for patients with Type A molybdenum cofactor deficiency (MoCD).

Recent Quotes

Symbol Price Chg Chg % Market Cap
ALXN 149.80 +0.75 +0.50% 29.50B
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.